Ligand Pharmaceuticals | LGND - Pre Tax Profit


Ligand Pharmaceuticals reported $141.14M in Pre-Tax Profit for its fiscal quarter ending in September of 2025.





Pre Tax Profit Change Date
Agenus USD -10.61M 263.52M Dec/2025
Amgen USD 3.92B 2.35B Sep/2025
Anika Therapeutics USD 764K 3M Dec/2025
Arrowhead Research USD 28.27M 7.85M Dec/2025
Baxter International USD 121M 12M Sep/2025
Bristol-Myers Squibb USD 3.11B 1.34B Sep/2025
Eli Lilly USD 7.23B 456M Sep/2025
Enanta Pharmaceuticals USD -22.71M 95.08M Dec/2024
Enviri Corporation USD 361.08M 15.18M Sep/2025
Gilead Sciences USD 3.64B 1.21B Sep/2025
GlaxoSmithKline GBP 1.23B 1.23B Dec/2025
Glaxosmithkline GBP 2.46B 569M Sep/2025
Heron Therapeutics USD -2.95M 14.54M Dec/2025
Insmed USD -326.93M 41.77M Dec/2025
Intrexon USD -60.48M 27.09M Jun/2024
Ionis Pharmaceuticals USD -228M 99M Dec/2025
Karyopharm Therapeutics USD -39.9M 9.01M Dec/2025
Ligand Pharmaceuticals USD 141.14M 102M Sep/2025
MacroGenics USD -14.93M 31.75M Dec/2025
Merck USD 6.74B 22M Sep/2025
Pacira USD 9.52M 11.45M Sep/2025
Pfizer USD 3.33B 290M Sep/2025
Rigel Pharmaceuticals USD -1.03M 7.22M Jun/2024
Sangamo BioSciences USD -36.05M 12.94M Jun/2024
Veracyte USD 40.63M 21.74M Dec/2025